News
Seres’ ulcerative colitis candidate misses primary endpoint in mid-stage study
Microbiome therapeutics company Seres Therapeutics has announced that a Phase IIb study of its potential ulcerative colitis (UC) candidate SER-287 failed to meet its primary endpoint.